Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy"
J Hepatol
.
2021 Oct;75(4):1007-1008.
doi: 10.1016/j.jhep.2021.07.009.
Epub 2021 Jul 19.
Authors
Sergio M Borgia
1
,
Stephen D Shafran
2
Affiliations
1
Division of Infectious Diseases, William Osler Health System, Brampton, Canada. Electronic address: sergio.borgia@williamoslerhs.ca.
2
Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
PMID:
34293344
DOI:
10.1016/j.jhep.2021.07.009
No abstract available
Publication types
Letter
Comment
MeSH terms
Carbamates
Hepatitis C, Chronic* / drug therapy
Heterocyclic Compounds, 4 or More Rings
Humans
Renal Dialysis
Sofosbuvir*
Substances
Carbamates
Heterocyclic Compounds, 4 or More Rings
velpatasvir
Sofosbuvir